Characteristics of Induced-Sputum Inflammatory Phenotypes in Adults with Asthma: Predictors of Bronchial Eosinophilia

References

• Djukanovic´ R, Sterk PJ, Fahy JV, Hargreave FE. Standardized methodology of sputum induction and processing. Eur Respir J. 2002;20(Supplement 37):1–52, 4. doi:10.1183/09031936.02.00000102
   PubMedGoogle Scholar
• Spanevello A, Confalonieri M, Sulotto F, et al. Induced sputum cellularity: reference values and distribution in normal volunteers. Am J Respir Crit Care Med. 2000;162(3):1.172–1174. doi:10.1164/ajrccm.162.3.9908057
   Web of Science ®Google Scholar
• Schleich FN, Manise M, Sele J, Henket M, Seidel L, Louis R. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med. 2013;13:11. doi:10.1186/1471-2466-13-11
   PubMed Web of Science ®Google Scholar
• Robinson D, Humbert M, Buhl R, et al. Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017;47:1365–2222. doi:10.1111/cea.12880
   Web of Science ®Google Scholar
• Aziz-Ur-Rehman A, Dasgupta A, Kjarsgaard M, Hargreave FE, Nair P. Sputum cell counts to manage prednisone-dependent asthma: effects on FEV1 and eosinophilic exacerbations. Allergy Asthma Clin Immunol. 2017;13(1):17. doi:10.1186/s13223-017-0190-0
   PubMedGoogle Scholar
• Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax. 2002;57(10):875–879.
   PubMed Web of Science ®Google Scholar
• Park SY, Kang SY, Song WJ, Kim JH. Evolving concept of severe asthma: transition from diagnosis to treatable traits. Allergy Asthma Immunol Res. 2022;14(5):447–464. doi:10.4168/aair.2022.14.5.447
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973–984. doi:10.1056/NEJMoa0808991
   PubMed Web of Science ®Google Scholar
• Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European respiratory society/American thoracic society guideline. Eur Respir J. 2020;55(1):1900588. doi:10.1183/13993003.00588-2019
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled Phase 3 trial. Lancet. 2016;388(10056):2115–2127. doi:10.1016/S0140-6736(16)31324-1
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. doi:10.1016/S0140-6736(16)31322-8
   PubMed Web of Science ®Google Scholar
• Domingo RC, Carrillo DT, Blanco AM, Martínez ME, Banas CD, Sánchez HMG; REDES Study Group. Correction to: rEal worlD effectiveness and safety of mepolizumab in a multicentric Spanish cohort of asthma patients stratified by Eosinophils: the REDES study. Drugs. 2021;81(16):1949–1951. doi:10.1007/s40265-021-01622-x
   PubMed Web of Science ®Google Scholar
• Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4(7):549–556. doi:10.1016/S2213-2600(16)30031-5
   PubMed Web of Science ®Google Scholar
• GEMA. Guía Española para el Manejo del Asma (GEMA 5.2). Available from: http://gemasma.com. Accessed January 9, 2023.
   Google Scholar
• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention; 2021. Available from: https://ginasthma.org/. Accessed January 9, 2023.
   Google Scholar
• Wagener AH, de Nijs SB, Lutter R, et al. External validation of blood eosinophils, FeNO and serum periostin as surrogates for sputum eosinophils in asthma. Thorax. 2015;70:115–120. doi:10.1136/thoraxjnl-2014-205634
   PubMed Web of Science ®Google Scholar
• Westerhof GA, Korevaar DA, Amelink M, et al. Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes. Eur Respir J. 2015;46(3):688–696. doi:10.1183/09031936.00012415
   PubMed Web of Science ®Google Scholar
• Heffler E, Terranova G, Chessari C, et al. Point-of-care blood eosinophil count in a severe asthma clinic setting. Ann Allergy Asthma Immunol. 2017;119(1):16–20. doi:10.1016/j.anai.2017.05.016
   PubMed Web of Science ®Google Scholar
• Sinz H, Renz H, Skevaki C. Cellular and noncellular bloodborne biomarkers in asthma. Ann Allergy Asthma Immunol. 2017;118(6):672–679. doi:10.1016/j.anai.2017.04.016
   PubMed Web of Science ®Google Scholar
• Menzella F, Biava M, Bagnasco D, et al. Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors? Drugs in Context. 2019;8:212580. doi:10.7573/dic.212580
   PubMedGoogle Scholar
• Tiotiu A. Biomarkers in asthma: state of the art. Asthma Res Pract. 2018;4(1):10. doi:10.1186/s40733-018-0047-4
   PubMedGoogle Scholar
• Lex C, Ferreira F, Zacharasiewicz A, et al. Airway eosinophilia in children with severe asthma: predictive values of non-invasive tests. Am J Respir Crit Care Med. 2006;174(12):1286–1291. doi:10.1164/rccm.200603-352OC
   PubMed Web of Science ®Google Scholar
• Lim S, Jatakanon A, Meah S, Oates T, Chung KF, Barnes PJ. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in mild to moderately severe asthma. Thorax. 2000;55(3):184–188. doi:10.1136/thorax.55.3.184
   PubMed Web of Science ®Google Scholar
• Kharitonov SA, Robbins RA, Yates D, Keatings V, Barnes PJ. Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am J Respir Crit Care Med. 1995;152(2):609–612. doi:10.1164/ajrccm.152.2.7543345
   PubMed Web of Science ®Google Scholar
• Olin AC, Rosengren A, Thelle DS, Lissner L, Bake B, Torén K. Height, age, and atopy are associated with fraction of exhaled nitric oxide in a large adult general population sample. Chest. 2006;130(5):1319–1325. doi:10.1378/chest.130.5.1319
   PubMed Web of Science ®Google Scholar
• Strunk RC, Szefler SJ, Phillips BR, et al. Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. J Allergy Clin Immunol. 2003;112(5):883–892. doi:10.1016/j.jaci.2003.08.014
   PubMed Web of Science ®Google Scholar
• Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax. 1998;53(2):91–95. doi:10.1136/thx.53.2.91
   PubMed Web of Science ®Google Scholar
• Jones SL, Kittelson J, Cowan JO, et al. The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control. Am J Respir Crit Care Med. 2001;164(5):738–743. doi:10.1164/ajrccm.164.5.2012125
   PubMed Web of Science ®Google Scholar
• Berry MA, Shaw DE, Green RH, et al. The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin Exp Allergy. 2005;35(9):1175–1179. doi:10.1111/j.1365-2222.2005.02314.x
   PubMed Web of Science ®Google Scholar
• Vega JM, Badia X, Badiola C, et al. Validation of the Spanish version of the asthma control test (ACT). J Asthma. 2007;44(10):867–872. doi:10.1080/02770900701752615
   PubMed Web of Science ®Google Scholar
• Perpiñá M, Belloch A, Pascual LM, de Diego A, Compte L. The quality of life in asthma: an evaluation of the AQLQ questionnaire for its use on a Spanish population. Asthma quality of life questionnaire. Arch Bronconeumol. 1995;31(5):211–218. doi:10.1016/S0300-2896(15)30926-1
   PubMedGoogle Scholar
• Bernstein IL, Li JT, Bernstein DI, et al. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol. 2008;100(3 Suppl 3):S1–148. doi:10.1016/s1081-1206(10)60305-5
   PubMed Web of Science ®Google Scholar
• Miller MR, Crapo R, Hankinson J, et al; ATS/ERS Task Force. General considerations for lung function testing. Eur Respir J. 2005;1:153–161. doi:10.1183/09031936.05.00034505
   Google Scholar
• Roca J, Sanchis J, Agusti-Vidal A, et al. Spirometric reference values from a Mediterranean population. Bull Eur Physiopathol Respir. 1986;22(3):217–224.
   PubMedGoogle Scholar
• American Thoracic Society/European Respiratory Society (ATS/ERS). ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171(8):912–930. doi:10.1164/rccm.200406-710ST
   PubMed Web of Science ®Google Scholar
• Dweik RA, Boggs PB, Erzurum SC, et al. American thoracic society committee on interpretation of exhaled nitric oxide levels (FeNO) for clinical applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications. Am J Respir Crit Care Med. 2011;5:602–615. doi:10.1164/rccm.9120-11ST
   Google Scholar
• Yancey SW, Keene ON, Albers FC, et al. Biomarkers for severe eosinophilic asthma. J Allergy Clin Immunol. 2017;140(6):1509–1518. doi:10.1016/j.jaci.2017.10.005
   PubMed Web of Science ®Google Scholar
• Suárez-Cuartín G, Crespo A, Mateus E, et al. Variability in asthma inflammatory phenotypes in induced sputum. Frequency and causes. Arch Bronconeumol. 2016;52(2):76–81. doi:10.1016/j.arbres.2015.03.007
   PubMed Web of Science ®Google Scholar
• Hastie AT, Moore WC, Li H, et al; National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol. 2013;132(1):72–80. doi:10.1016/j.jaci.2013.03.044
   PubMed Web of Science ®Google Scholar
• Rial MJ, Álvarez‐puebla MJ, Arismendi E, et al. Clinical and inflammatory characteristics of patients with asthma in the Spanish MEGA project cohort. Clin Transl Allergy. 2021;11:e12001. doi:10.1002/clt2.12001
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. doi:10.1016/S0140-6736(12)60988-X
   PubMed Web of Science ®Google Scholar
• Brussino L, Heffler E, Bucca C, Nicola S, Rolla G. Eosinophils target therapy for severe asthma: critical points. Biomed Res Int. 2018;2018:7582057. doi:10.1155/2018/7582057
   PubMed Web of Science ®Google Scholar
• Wark PA, McDonald VM, Gibson PG. Adjusting prednisone using blood eosinophils reduces exacerbations and improves asthma control in difficult patients with asthma. Respirology. 2015;20(8):1282–1284. doi:10.1111/resp.12602
   PubMed Web of Science ®Google Scholar
• Korevaar DA, Westerhof GA, Wang J, et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(4):290–300. doi:10.1016/S2213-2600(15)00050-8
   PubMed Web of Science ®Google Scholar
• Taylor DR. Advances in the clinical applications of exhaled nitric oxide measurements. J Breath Res. 2012;6(4):047102. doi:10.1088/1752-7155/6/4/047102
   PubMed Web of Science ®Google Scholar
• Pelaia C, Vatrella A, Gallelli L, et al. Dupilumab for the treatment of asthma. Expert Opin Biol Ther. 2017;17(12):1565–1572. doi:10.1080/14712598.2017.1387245
   PubMed Web of Science ®Google Scholar
• Busse WW, Maspero JF, Rabe KF, et al. Liberty asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma. Adv Ther. 2018;35(5):737–748. doi:10.1007/s12325-018-0702-4
   PubMed Web of Science ®Google Scholar
• Crespo A, Giner J, Torrejón M, et al. Clinical and inflammatory features of asthma with dissociation between fractional exhaled nitric oxide and eosinophils in induced sputum. J Asthma. 2016;53(5):459–464. doi:10.3109/02770903.2015.1116086
   PubMed Web of Science ®Google Scholar
• Demarche SF, Schleich FN, Paulus VA, Henket MA, Van Hees TJ, Louis RE. Is it possible to claim or refute sputum eosinophils ≥ 3% in asthmatics with sufficient accuracy using biomarkers? Respir Res. 2017;18(1):133. doi:10.1186/s12931-017-0615-9
   PubMedGoogle Scholar
• Ntontsi P, Loukides S, Bakakos P, et al. Clinical, functional and inflammatory characteristics in patients with paucigranulocytic stable asthma: comparison with different sputum phenotypes. Allergy. 2017;72(11):1761–1767.
   PubMed Web of Science ®Google Scholar
• Laidlaw T, Mullol J, Woessner K, Amin N, Mannent L. Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract. 2021;9(3):1133–1141. doi:10.1016/j.jaip.2020.09.063
   PubMed Web of Science ®Google Scholar
• Denton E, Price D, Tran T, et al. Cluster analysis of inflammatory biomarker expression in the international severe asthma registry. J Allergy Clin Immunol Pract. 2021;9(7):2680–2688. doi:10.1016/j.jaip.2021.02.059
   PubMed Web of Science ®Google Scholar
• Abdo M, Pedersen F, Kirsten A-M, et al. Longitudinal impact of sputum inflammatory phenotypes on small airway dysfunction and disease outcomes in asthma. J Allergy Clin Immunol Pract. 2022;10(6):1545–1553.
   PubMed Web of Science ®Google Scholar